- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07268248
1-timmars Premedicinering för Allergimål på Akuten: PAGE-1-studien (PAGE1)
1-timmars Premedicinering för Allergimål vid Akut Datortomografi, En Multicenter Randomiserad Kontrollerad Icke-underlägeshetsstudie: PAGE-1-Studien
1-hour Premedication for Allergy Goal in Emergency: PAGE-1 is a prospective, parallel, two-arm, non-inferiority, randomized controlled trial evaluating the safety of a 1-hour (intervention) versus a 4-hour (standard regimen) intravenous (IV) premedication protocol in adult patients in the Emergency Department (ED) with a documented iodinated contrast allergy and requiring computed tomography (CT) imaging for a high-risk indication.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Allergic or hypersensitivity reactions to iodinated contrast media are rare, estimated to occur in 0.3% to 1.4% of cases, but have decreased significantly after the switch from high-osmolar to low-osmolar contrast. Most reactions are mild, and breakthrough reactions occur regardless of the timing of premedication. IV premedication is recommended, but there is no level I evidence for its basis in the ED.
This study addresses the sparse evidence that underpins the ubiquitous multi-hour premedication protocols in EDs nationwide. It specifically challenges the existing paradigm of 4-5 hours of IV premedication, which has remarkably never been prospectively validated.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Chirag N Shah, MD
- Telefonnummer: 732-235-8717
- E-post: shahcn@rwjms.rutgers.edu
Studieorter
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Rutgers, Robert Wood Johnson Hospital
-
Kontakt:
- Paul Peng, MD PhD MS
-
Kontakt:
- Chirag Shah, MD
- Telefonnummer: 7322358717
- E-post: chirag.shah.md@rutgers.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adult (≥ 21 years old)
- Documented iodinated contrast allergy in the electronic health record
- CT with iodinated contrast ordered for a high-risk indication, † defined as post-arrest, concern for aortic dissection, ischemia, occlusion, obstruction, or other life-threatening conditions requiring timely diagnosis
- Willing and able to give consent
Exclusion Criteria:
- Previous enrollment in this study
- Pregnancy
- Seafood or iodine allergy, alone
- Gadolinium allergy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 1-hour Premedication Protocol
IV glucocorticoid and antihistamine 1 hour before contrast |
Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately plus diphenhydramine 25 mg IV 1 hour before contrast medium administration for CT imaging |
|
Aktiv komparator: 4-hour Premedication Protocol
IV glucocorticoid 4 hours before contrast and IV antihistamine 1 hour before contrast |
Methylprednisolone sodium succinate (e.g., Solu-Medrol®) 40 mg IV immediately 4 hours before contrast medium administration, plus diphenhydramine 25 mg IV 1 hour before contrast for CT imaging |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Difference in proportion of Acute Contrast Reaction
Tidsram: 30 minutes
|
Measurement of any contrast reaction after contrast administration |
30 minutes
|
|
Proportion of patients eligible for intervention
Tidsram: Before randomization
|
Ratio of those eligible to screened |
Before randomization
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion randomized to intervention and control
Tidsram: Within 30 minutes after completion of CT imaging
|
Ratio of patients randomized to intervention and control arms, and who complete the protocol as specified |
Within 30 minutes after completion of CT imaging
|
|
Adverse events after intervention
Tidsram: Within 30 minutes after assessment of primary outcome
|
Proportion of patients who required intramuscular epinephrine, noninvasive ventilation, or intubation |
Within 30 minutes after assessment of primary outcome
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Paul Peng, Rutgers Robert Wood Johnson Medical School
Publikationer och användbara länkar
Allmänna publikationer
- Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990 Jun;175(3):621-8. doi: 10.1148/radiology.175.3.2343107.
- Davenport MS, Cohan RH. The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients. Radiol Clin North Am. 2017 Mar;55(2):413-421. doi: 10.1016/j.rcl.2016.10.012.
- Greenberger PA, Halwig JM, Patterson R, Wallemark CB. Emergency administration of radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1986 Apr;77(4):630-4. doi: 10.1016/0091-6749(86)90357-x.
- Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber FH, Stolberg HO. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987 Oct 1;317(14):845-9. doi: 10.1056/NEJM198710013171401.
- Amiri E. Optimizing Premedication Strategies for Iodinated Contrast Media in CT scans: A Literature Review. J Med Imaging Radiat Sci. 2025 Jan;56(1):101782. doi: 10.1016/j.jmir.2024.101782. Epub 2024 Nov 20.
- Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol. 2001 Jun;176(6):1389-92. doi: 10.2214/ajr.176.6.1761389.
- Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT. AJR Am J Roentgenol. 2015 Jul;205(1):77-84. doi: 10.2214/AJR.14.13810.
- Mervak BM, Cohan RH, Ellis JH, Khalatbari S, Davenport MS. Intravenous Corticosteroid Premedication Administered 5 Hours before CT Compared with a Traditional 13-Hour Oral Regimen. Radiology. 2017 Nov;285(2):425-433. doi: 10.1148/radiol.2017170107. Epub 2017 Jul 26.
- Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol. 2008 Aug;191(2):409-15. doi: 10.2214/AJR.07.3421.
- Goldfarb JW. National trends in contrast media enhanced and unenhanced computed tomography use. Clin Imaging. 2023 Jan;93:103-105. doi: 10.1016/j.clinimag.2022.11.009. Epub 2022 Nov 17. No abstract available.
- Berlyand Y, Fraga JA, Succi MD, Yun BJ, Lee AH, Baugh JJ, Whitehead D, Raja AS, Prabhakar AM. Impact of iodinated contrast allergies on emergency department operations. Am J Emerg Med. 2022 Nov;61:127-130. doi: 10.1016/j.ajem.2022.08.052. Epub 2022 Sep 5.
- Wang C, Ramsey A, Lang D, Maria Copaescu A, Krishnan P, Kuruvilla M, Mervak B, Newhouse J, Sumkin A, Saff R. Management and Prevention of Hypersensitivity Reactions to Radiocontrast Media: A Consensus Statement from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology. Radiology. 2025 May;315(2):e240100. doi: 10.1148/radiol.240100.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Immunsystemets sjukdomar
- Överkänslighet
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Histaminmedel
- Neurotransmittormedel
- Administration
- Sjukvårdskvalitet, tillgång och utvärdering
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Hälsovårdskvalitet
- Kvalitetsindikatorer, hälsovård
- Binjurhormoner
- Glukokortikoider
- Histaminantagonister
- Vårdstandard
Andra studie-ID-nummer
- Pro2025002416
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Study protocol and statistical plan
Tidsram för IPD-delning
Available after start date and 1 year after end of study
Kriterier för IPD Sharing Access
Study coordinators and key personnel
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .